[關(guān)鍵詞]
[摘要]
摘 要:散發(fā)性腎透明細(xì)胞癌中存在凡黑普爾-林道基因的突變,腎癌細(xì)胞的生長主要依賴血管內(nèi)皮生長因子(VEGF),因此,以VEGF為靶點的藥物廣泛應(yīng)用于腎癌的臨床治療。重組性單克隆抗體(如貝伐單抗)和與VEGF受體相結(jié)合的小分子抑制劑(如舒尼替尼、索拉非尼、阿西替尼、帕唑帕尼、瓦他拉尼)臨床療效已得到了驗證,表現(xiàn)出較高的應(yīng)答率、無進(jìn)展生存時間的延長并提高了腎癌患者總生存率。就VEGF抑制劑的作用靶點、機(jī)制、治療后患者敏感性以及臨床試驗等做一簡要綜述,為抗腫瘤藥物研發(fā)提供思路。
[Key word]
[Abstract]
Abstract:Von hippel-lindau gene mutation is very common in sporadic renal cell carcinoma,and vascular endothelial growth factor(VEGF)plays an important role in the growth of cancer cells.Therefore,VEGF-targeted drugs have been widely used in clinic treatment of renal cell carcinoma.Many VEGF-targeted drugs have been proved good therapeutic effects,including recombinant monoclonal antibodies(such as Bevacizumab)and small-molecule inhibitors that bind with VEGF receptors(such as Sunitinib,Sorafenib,Axitinib,Pazopanib,and Vatalanib).Those medicines prolong the progression-free survival(PFS)and increase total survival rate of patients with renal cell carcinoma.This paper reviews the target site,function mechanism,patient sensitivity and clinic test of VEGF-targeted drugs,so as to provide certain help for the research and development of anti-tumor drugs.
[中圖分類號]
[基金項目]